Recent advances in the treatment of Brugada syndrome

References

• Antzelevitch C, Yan GX. J wave syndromes. Heart Rhythm. 2010 Apr;7:549–558.
   PubMed Web of Science ®Google Scholar
• Nam GB, Kim YH, Antzelevitch C. Augmentation of J waves and electrical storms in patients with early repolarization. N Engl J Med. 2008 May 8;358:2078–2079.
   PubMed Web of Science ®Google Scholar
• Haissaguerre M, Derval N, Sacher F, et al. Sudden cardiac arrest associated with early repolarization. N Engl J Med. 2008 May 8;358:2016–2023.
   PubMed Web of Science ®Google Scholar
• Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol. 1992 Nov 15;20:1391–1396.
   PubMed Web of Science ®Google Scholar
• Kanter RJ, Pfeiffer R, Hu D, et al. Brugada-like syndrome in infancy presenting with rapid ventricular tachycardia and intraventricular conduction delay. Circulation. 2012 Jan 3;125:14–22.
   PubMed Web of Science ®Google Scholar
• Antzelevitch C. Molecular biology and cellular mechanisms of Brugada and long QT syndromes in infants and young children. J Electrocardiol. 2001 Sep;34:177–181.
   PubMed Web of Science ®Google Scholar
• Wedekind H, Smits JP, Schulze-Bahr E, et al. De novo mutation in the SCN5A gene associated with early onset of sudden infant death. Circulation. 2001 Sep 4;104:1158–1164.
   PubMed Web of Science ®Google Scholar
• Conte G, Levinstein M, Sarkozy A, et al. Brugada syndrome in the elderly. Eur Heart J. 2013;34:319.
   PubMedGoogle Scholar
• Hermida JS, Lemoine JL, Aoun FB, et al. Prevalence of the Brugada syndrome in an apparently healthy population. Am J Cardiol. 2000 Jul 1;86:91–94.
   PubMed Web of Science ®Google Scholar
• Gallagher MM, Forleo GB, Behr ER, et al. Prevalence and significance of Brugada-type ECG in 12,012 apparently healthy European subjects. Int J Cardiol. 2008 10 30;130:44–48.
   PubMed Web of Science ®Google Scholar
• Postema PG. About Brugada syndrome and its prevalence. Europace. 2012 Jul 1;14:925–928.
   PubMed Web of Science ®Google Scholar
• Patel SS, Anees SS, Ferrick KJ. Prevalence of a Brugada pattern electrocardiogram in an urban population in the United States. Pacing Clin Electrophysiol. 2009 Jun;32:704–708.
   PubMed Web of Science ®Google Scholar
• Pecini R, Cedergreen P, Theilade S, et al. The prevalence and relevance of the Brugada-type electrocardiogram in the Danish general population: data from the Copenhagen City Heart Study. Europace. 1907 Jul 20;12:982–986.
   Google Scholar
• Sinner MF, Pfeufer A, Perz S, et al. Spontaneous Brugada electrocardiogram patterns are rare in the German general population: results from the KORA study. Europace. 2009;11:1338–1344.
   PubMed Web of Science ®Google Scholar
• Uhm JS, Hwang IU, Oh YS, et al. Prevalence of electrocardiographic findings suggestive of sudden cardiac death risk in 10,867 apparently healthy young Korean men. Pacing Clin Electrophysiol. 2011;34:717–723.
   PubMed Web of Science ®Google Scholar
• Letsas KP, Gavrielatos G, Efremidis M, et al. Prevalence of Brugada sign in a Greek tertiary hospital population. Europace. 2007;9:1077–1080.
   PubMed Web of Science ®Google Scholar
• Matsuo K, Akahoshi M, Nakashima E, et al. The prevalence, incidence and prognostic value of the Brugada-type electrocardiogram: a population-based study of four decades. J Am Coll Cardiol. 2001;38:765–770.
   PubMed Web of Science ®Google Scholar
• Shi S, Barajas-Martinez H, Liu T, et al. Prevalence of spontaneous Brugada ECG pattern recorded at standard intercostal leads: a meta-analysis. Int J Cardiol. 2017;254:151–156.
   Web of Science ®Google Scholar
• Juang JM, Phan WL, Chen PC, et al. Brugada-type electrocardiogram in the Taiwanese population–is it a risk factor for sudden death? J Formos Med Assoc. 2011;110:230–238.
   PubMed Web of Science ®Google Scholar
• Gervacio-Domingo G, Isidro J, Tirona J, et al. The Brugada type 1 electrocardiographic pattern is common among Filipinos. J Clin Epidemiol. 2008;61:1067–1072.
   PubMed Web of Science ®Google Scholar
• Nademanee K, Veerakul G, Nimmannit S, et al. Arrhythmogenic marker for the sudden unexplained death syndrome in Thai men. Circulation. 1997;96:2595–2600.
   PubMed Web of Science ®Google Scholar
• Tsuji H, Sato T, Morisaki K, et al. Prognosis of subjects with Brugada-type electrocardiogram in a population of middle-aged Japanese diagnosed during a health examination. Am J Cardiol. 2008 Sep 1;102:584–587.
   PubMed Web of Science ®Google Scholar
• Furuhashi M, Uno K, Tsuchihashi K, et al. Prevalence of asymptomatic ST segment elevation in right precordial leads with right bundle branch block (Brugada-type ST shift) among the general Japanese population. Heart. 2001;86:161–166.
   PubMed Web of Science ®Google Scholar
• Miyasaka Y, Tsuji H, Yamada K, et al. Prevalence and mortality of the Brugada-type electrocardiogram in one city in Japan. J Am Coll Cardiol. 2001;38:771–774.
   PubMed Web of Science ®Google Scholar
• Probst V, Veltmann C, Eckardt L, et al. Long-term prognosis of patients diagnosed with Brugada syndrome: results from the FINGER Brugada Syndrome Registry. Circulation. 2010 Feb 9;121:635–643.
   PubMed Web of Science ®Google Scholar
• Eckardt L, Kirchhof P, Johna R, et al. Wolff-Parkinson-White syndrome associated with Brugada syndrome. Pacing Clin Electrophysiol. 2001;24:1423–1424.
   PubMed Web of Science ®Google Scholar
• Morita H, Fukushima-Kusano K, Nagase S, et al. Sinus node function in patients with Brugada-type ECG. Circ J. 2004;68:473–476.
   PubMed Web of Science ®Google Scholar
• Morita H, Kusano-Fukushima K, Nagase S, et al. Atrial fibrillation and atrial vulnerability in patients with Brugada syndrome. J Am Coll Cardiol. 2002 Oct 16;40:1437–1444.
   PubMed Web of Science ®Google Scholar
• Wilde AA, Antzelevitch C, Borggrefe M, et al. Proposed diagnostic criteria for the Brugada syndrome. Eur Heart J. 2002;23:1648–1654.
   PubMed Web of Science ®Google Scholar
• Antzelevitch C, Brugada P, Borggrefe M, et al. Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation. 2005 Jan 17;111:659–670.
   PubMed Web of Science ®Google Scholar
• Priori SG, Wilde AA, Horie M, et al. Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Heart Rhythm. 2013 Oct 1;15:1389–1406.
   Google Scholar
• Michowitz Y, Milman A, Sarquella-Brugada G, et al. Fever-related arrhythmic events in the multicenter survey on arrhythmic events in Brugada syndrome. Heart Rhythm. 2018 Apr 9.  pii: S1547-5271(18)30346-1. doi:10.1016/j.hrthm.2018.04.007. [Epub ahead of print].
   Google Scholar
• Antzelevitch C, Yan GX, Ackerman MJ, et al. J-Wave syndromes expert consensus conference report: emerging concepts and gaps in knowledge. Journal of Arrhythmia. 2016;32(5):315-339. doi:10.1016/j.joa.2016.07.002.
   Google Scholar
• Baranchuk A, Nguyen T, Ryu MH, et al. Brugada phenocopy: new terminology and proposed classification. Ann Noninvasive Electrocardiol. 2012;17:299–314.
   PubMed Web of Science ®Google Scholar
• Kocabas U, Hasdemir C, Kaya E, et al. Brugada syndrome, Brugada phenocopy or none? Ann Noninvasive Electrocardiol. 2017 Jun 13;22:e12470.
   PubMed Web of Science ®Google Scholar
• Bayes de Luna A, Brugada J, Baranchuk A, et al. Current electrocardiographic criteria for diagnosis of Brugada pattern: a consensus report. J Electrocardiol. 2012;45:433–442.
   PubMed Web of Science ®Google Scholar
• Garcia-Niebla J, Llontop-Garcia P, Valle-Racero JI, et al. Technical mistakes during the acquisition of the electrocardiogram. Ann Noninvasive Electrocardiol. 2009;14:389–403.
   PubMed Web of Science ®Google Scholar
• Garcia-Niebla J, Serra-Autonell G. Effects of inadequate low-pass filter application. J Electrocardiol. 2009 Jul;42:303–304.
   PubMed Web of Science ®Google Scholar
• Hasdemir C, Payzin S, Kocabas U, et al. High prevalence of concealed Brugada syndrome in patients with atrioventricular nodal reentrant tachycardia. Heart Rhythm. 2015 Jul;12:1584–1594.
   PubMed Web of Science ®Google Scholar
• Conte G, De Asmundis C, Ciconte G, et al. Follow-up from childhood to adulthood of individuals with family history of Brugada syndrome and normal electrocardiograms. JAMA. 2014 Nov 19;312:2039–2041.
   PubMed Web of Science ®Google Scholar
• Conte G, Dewals W, Sieira J, et al. Drug-induced Brugada syndrome in children: clinical features, device-based management and long-term follow-up. J Am Coll Cardiol. 2014 Jun 3;63:2272–2279.
   PubMed Web of Science ®Google Scholar
• Conte G, Sieira J, Sarkozy A, et al. Life-threatening ventricular arrhythmias during ajmaline challenge in patients with Brugada syndrome: incidence, clinical features, and prognosis. Heart Rhythm. 2013 Dec;10:1869–1874.
   PubMed Web of Science ®Google Scholar
• Dobbels B, De Cleen D, Ector J. Ventricular arrhythmia during ajmaline challenge for the Brugada syndrome. Europace. 2016 Oct;18:1501–1506.
   PubMed Web of Science ®Google Scholar
• Kalla H, Yan GX, Marinchak R. Ventricular fibrillation in a patient with prominent J (Osborn) waves and ST segment elevation in the inferior electrocardiographic leads: a Brugada syndrome variant? J Cardiovasc Electrophysiol. 2000 Jan;11:95–98.
   PubMed Web of Science ®Google Scholar
• Horigome H, Shigeta O, Kuga K, et al. Ventricular fibrillation during anesthesia in association with J waves in the left precordial leads in a child with coarctation of the aorta. J Electrocardiol. 2003;36:339–343.
   PubMed Web of Science ®Google Scholar
• Letsas KP, Sacher F, Probst V, et al. Prevalence of early repolarization pattern in inferolateral leads in patients with Brugada syndrome. Heart Rhythm. 2008;5:1685–1689.
   PubMed Web of Science ®Google Scholar
• Kawata H, Morita H, Yamada Y, et al. Prognostic significance of early repolarization in inferolateral leads in Brugada patients with documented ventricular fibrillation: a novel risk factor for Brugada syndrome with ventricular fibrillation. Heart Rhythm. 2013;10:1161–1168.
   PubMed Web of Science ®Google Scholar
• Takagi M, Aonuma K, Sekiguchi Y, et al. The prognostic value of early repolarization (J wave) and ST-segment morphology after J wave in Brugada syndrome: multicenter study in Japan. Heart Rhythm. 2013;10:533–539.
   PubMed Web of Science ®Google Scholar
• Raju H, Papadakis M, Govindan M, et al. Low prevalence of risk markers in cases of sudden death due to brugada syndrome relevance to risk stratification in brugada syndrome. J Am Coll Cardiol. 2011 Jun 7;57:2340–2345.
   PubMedGoogle Scholar
• Milman A, Andorin A, Gourraud JB, et al. Profile of Brugada syndrome patients presenting with their first documented arrhythmic event: Data from the Survey on Arrhythmic Events in BRUgada Syndrome (SABRUS). Heart Rhythm. 2018;15:716–724.
   Google Scholar
• Okamura H, Kamakura T, Morita H, et al. Risk stratification in patients with Brugada syndrome without previous cardiac arrest - prognostic value of combined risk factors. Circ J. 2015;79:310–317.
   PubMed Web of Science ®Google Scholar
• Brugada J, Brugada R, Brugada P. Determinants of sudden cardiac death in individuals with the electrocardiographic pattern of Brugada syndrome and no previous cardiac arrest. Circulation. 2003 Dec 23;108:3092–3096.
   PubMed Web of Science ®Google Scholar
• Priori SG, Napolitano C, Gasparini M, et al. Natural history of Brugada syndrome: insights for risk stratification and management. Circulation. 2002 Mar 19;105:1342–1347.
   PubMed Web of Science ®Google Scholar
• Sieira J, Conte G, Ciconte G, et al. A score model to predict risk of events in patients with Brugada Syndrome. Eur Heart J. 2017 Jun 7;38:1756–1763.
   PubMed Web of Science ®Google Scholar
• Ikeda T, Sakurada H, Sakabe K, et al. Assessment of noninvasive markers in identifying patients at risk in the Brugada syndrome: insight into risk stratification. JAmCollCardiol. 2001;37:1628–1634.
   Google Scholar
• Huang Z, Patel C, Li W, et al. Role of signal-averaged electrocardiograms in arrhythmic risk stratification of patients with Brugada syndrome: a prospective study. Heart Rhythm. 2009;6:1156–1162.
   PubMed Web of Science ®Google Scholar
• Yoshioka K, Amino M, Zareba W, et al. Identification of high-risk brugada syndrome patients by combined analysis of late potential and T-wave amplitude variability on ambulatory electrocardiograms. Circ J. 2013 Feb 25;77:610–618.
   PubMed Web of Science ®Google Scholar
• Priori SG, Gasparini M, Napolitano C, et al. Risk stratification in Brugada syndrome: results of the PRELUDE (PRogrammed ELectrical stimUlation preDictive valuE) registry. J Am Coll Cardiol. 2012;59:37–45.
   PubMed Web of Science ®Google Scholar
• Morita H, Kusano KF, Miura D, et al. Fragmented QRS as a marker of conduction abnormality and a predictor of prognosis of Brugada syndrome. Circulation. 2008 Oct 21;118:1697–1704.
   PubMed Web of Science ®Google Scholar
• Junttila MJ, Brugada P, Hong K, et al. Differences in 12-lead electrocardiogram between symptomatic and asymptomatic Brugada syndrome patients. J Cardiovasc Electrophysiol. 2008;19:380–383.
   PubMed Web of Science ®Google Scholar
• Tatsumi H, Takagi M, Nakagawa E, et al. Risk stratification in patients with Brugada syndrome: analysis of daily fluctuations in 12-lead electrocardiogram (ECG) and signal-averaged electrocardiogram (SAECG). J Cardiovasc Electrophysiol. 2006;17:705–711.
   PubMed Web of Science ®Google Scholar
• Delise P, Allocca G, Marras E, et al. Risk stratification in individuals with the Brugada type 1 ECG pattern without previous cardiac arrest: usefulness of a combined clinical and electrophysiologic approach. EurHeart J. 2011;32:169–176.
   Google Scholar
• Sarkozy A, Sorgente A, Boussy T, et al. The value of a family history of sudden death in patients with diagnostic type I Brugada ECG pattern. EurHeart J. 2011 Sep 1;32:2153–2160.
   Google Scholar
• Sarkozy A, Paparella G, Boussy T, et al. The usefulness of the consensus clinical diagnostic criteria in Brugada syndrome. Int J Cardiol. 2013 Oct 9;167:2700–2704.
   PubMed Web of Science ®Google Scholar
• Gehi AK, Duong TD, Metz LD, et al. Risk stratification of individuals with the brugada electrocardiogram: a meta-analysis. J Cardiovasc Electrophysiol. 2006;17:577–583.
   PubMed Web of Science ®Google Scholar
• Paul M, Gerss J, Schulze-Bahr E, et al. Role of programmed ventricular stimulation in patients with Brugada syndrome: a meta-analysis of worldwide published data. EurHeart J. 2007;28:2126–2133.
   Google Scholar
• Giustetto C, Drago S, Demarchi PG, et al. Risk stratification of the patients with Brugada type electrocardiogram: a community-based prospective study. Europace. 2009;11:507–513.
   PubMed Web of Science ®Google Scholar
• Sroubek J, Probst V, Mazzanti A, et al. Programmed ventricular stimulation for risk stratification in the Brugada syndrome: a pooled analysis. Circulation. 2016 Jan 21;133:622–630.
   PubMed Web of Science ®Google Scholar
• Kamakura S, Ohe T, Nakazawa K, et al. Long-term prognosis of probands with Brugada-pattern ST-elevation in leads V1-V3. Circ Arrhythm Electrophysiol. 2009;2:495–503.
   PubMed Web of Science ®Google Scholar
• Conte G, Sieira J, Ciconte G, et al. Implantable cardioverter-defibrillator therapy in Brugada syndrome: a 20-year single-center experience. J Am Coll Cardiol. 2015;65:879–888.
   PubMed Web of Science ®Google Scholar
• Sieira J, Conte G, Ciconte G, et al. Clinical characterisation and long-term prognosis of women with Brugada syndrome. Heart. 2016;102:452–458.
   PubMed Web of Science ®Google Scholar
• Benito B, Sarkozy A, Mont L, et al. Gender differences in clinical manifestations of Brugada syndrome. J Am Coll Cardiol. 2008 Nov 4;52:1567–1573.
   PubMed Web of Science ®Google Scholar
• Sieira J, Brugada P. Brugada syndrome: defining the risk in asymptomatic patients. Arrhythm Electrophysiol Rev. 2016;5:164–169.
   PubMedGoogle Scholar
• Castro Hevia J, Antzelevitch C, Tornés Bárzaga F, et al. Tpeak-Tend and Tpeak-Tend dispersion as risk factors for ventricular tachycardia/ventricular fibrillation in patients with the Brugada syndrome. J Am Coll Cardiol. 2006 Feb 5;47:1828–1834.
   PubMed Web of Science ®Google Scholar
• Lambiase PD. Tpeak-Tend interval and Tpeak-Tend/QT ratio as markers of ventricular tachycardia inducibility in subjects with Brugada ECG phenotype. Europace. 2010 Feb;12:158–159.
   PubMedGoogle Scholar
• Wang JF, Shan QJ, Yang B, et al. [Tpeak-Tend interval and risk of cardiac events in patients with Brugada syndrome]. Zhonghua Xin Xue Guan Bing Za Zhi. 2007 Jul;35:629–632.
   PubMedGoogle Scholar
• Antzelevitch C, Di Diego JM, Argenziano M. Tpeak-Tend as a predictor of ventricular arrhythmogenesis. Int J Cardiol. 2017 Dec 15;249:75–76.
   PubMed Web of Science ®Google Scholar
• Talib AK, Sato N, Kawabata N, et al. Repolarization characteristics in early repolarization and Brugada syndromes: insight into an overlapping mechanism of lethal arrhythmias. J Cardiovasc Electrophysiol. 2014 Dec;25:1376–1384.
   PubMed Web of Science ®Google Scholar
• Makimoto H, Nakagawa E, Takaki H, et al. Augmented ST-segment elevation during recovery from exercise predicts cardiac events in patients with Brugada syndrome. J Am Coll Cardiol. 2010 Nov 2;56:1576–1584.
   PubMed Web of Science ®Google Scholar
• Makimoto H, Takaki H, Doi A, et al. Clinical significance of early heart rate recovery after exercising testing in patients with Brugada syndrome. Circulation. 2009 Nov 3;120:S671.
   Web of Science ®Google Scholar
• Guillem MS, Climent AM, Millet J, et al. Spatiotemporal characteristics of QRS complexes enable the diagnosis of Brugada syndrome regardless of the appearance of a type 1 ECG. J Cardiovasc Electrophysiol. 2016;27:563–570.
   PubMed Web of Science ®Google Scholar
• Calo L, Giustetto C, Martino A, et al. A new electrocardiographic marker of sudden death in Brugada syndrome: the S-wave in lead I. J Am Coll Cardiol. 2016 Mar 29;67:1427–1440.
   PubMed Web of Science ®Google Scholar
• Berne P, Brugada J. Brugada syndrome 2012. Circ J. 2012;76:1563–1571.
   PubMed Web of Science ®Google Scholar
• Antzelevitch C. J wave syndromes: molecular and cellular mechanisms. J Electrocardiol. 2013 Nov-Dec;46:510–518.
   PubMed Web of Science ®Google Scholar
• Antzelevitch C. Genetic, molecular and cellular mechanisms underlying the J wave syndromes. Circ J. 2012;76:1054–1065.
   PubMed Web of Science ®Google Scholar
• Kapplinger J, Tester D, Alders M, et al. An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. Heart Rhythm. 2010;7:33–46.
   PubMed Web of Science ®Google Scholar
• Chen Q, Kirsch GE, Zhang D, et al. Genetic basis and molecular mechanisms for idiopathic ventricular fibrillation. Nature. 1998 Mar 19;392:293–296.
   PubMed Web of Science ®Google Scholar
• London B, Michalec M, Mehdi H, et al. Mutation in glycerol-3-phosphate dehydrogenase 1 like gene (GPD1-L) decreases cardiac Na+ current and causes inherited arrhythmias. Circulation. 2007 Nov 13;116:2260–2268.
   PubMed Web of Science ®Google Scholar
• Antzelevitch C, Nof E. Brugada syndrome: recent advances and controversies. CurrCardiol Rep. 2008 Sep;10:376–383.
   PubMedGoogle Scholar
• Watanabe H, Koopmann TT, Le Scouarnec S, et al. Sodium channel beta1 subunit mutations associated with Brugada syndrome and cardiac conduction disease in humans. J Clin Invest. 2008;118:2260–2268.
   PubMed Web of Science ®Google Scholar
• Valdivia CR, Medeiros-Domingo A, Ye B, et al. Loss-of-function mutation of the SCN3B-encoded sodium channel b3 subunit associated with a case of idiopathic ventricular fibrillation. Cardiovasc Res. 2010 Jun 1;86:393–400.
   Web of Science ®Google Scholar
• Medeiros-Domingo A, Tan BH, Crotti L, et al. Gain-of-function mutation S422L in the KCNJ8-encoded cardiac K(ATP) channel Kir6.1 as a pathogenic substrate for J-wave syndromes. Heart Rhythm. 2010;7:1466–1471.
   PubMed Web of Science ®Google Scholar
• Giudicessi JR, Ye D, Tester DJ, et al. Transient outward current (Ito) gain-of-function mutations in the KCND3-encoded Kv4.3 potassium channel and Brugada syndrome. Heart Rhythm. 2011;8:1024–1032.
   PubMed Web of Science ®Google Scholar
• Kattygnarath D, Maugenre S, Neyroud N, et al. MOG1: a new susceptibility gene for Brugada syndrome. Circ Cardiovasc Genet. 2011;4:261–268.
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Sato A, Marcou CA, et al. A novel disease gene for Brugada syndrome: sarcolemmal membrane-associated protein gene mutations impair intracellular trafficking of hNav1.5. Circ ArrhythmElectrophysiol. 2012;5:1098–1107.
   PubMed Web of Science ®Google Scholar
• Hu D, Barajas-Martinez H, Terzic A, et al. ABCC9 is a novel Brugada and early repolarization syndrome susceptibility gene. Int J Cardiol. 2014 Feb 15;171:431–442.
   PubMed Web of Science ®Google Scholar
• Hu D, Barajas-Martinez H, Kahlig K, et al. Genetic variants in SCN10A associated with Brugada syndrome, right bundle branch block and atrioventricular block. Heart Rhythm. 2012 May 1;9:S395.
   Google Scholar
• Veerman CC, Podliesna S, Tadros R, et al. The Brugada syndrome susceptibility gene HEY2 modulates cardiac transmural ion channel patterning and electrical heterogeneity. Circ Res. 2017 Jun 21;121:537–548.
   PubMed Web of Science ®Google Scholar
• Antzelevitch C, Yan GX. J-wave syndromes: Brugada and early repolarization syndromes. Heart Rhythm. 2015 Aug;12:1852–1866.
   PubMed Web of Science ®Google Scholar
• Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm. 2011;8:1308–1339.
   PubMed Web of Science ®Google Scholar
• Park DS, Cerrone M, Morley G, et al. Genetically engineered SCN5A mutant pig hearts exhibit conduction defects and arrhythmias. J Clin Invest. 2015 Jan;125:403–412.
   PubMed Web of Science ®Google Scholar
• Burashnikov E, Pfeiffer R, Barajas-Martinez H, et al. Mutations in the cardiac L-type calcium channel associated J wave syndrome and sudden cardiac death. Heart Rhythm. 2010;7:1872–1882.
   PubMed Web of Science ®Google Scholar
• Cordeiro JM, Marieb M, Pfeiffer R, et al. Accelerated inactivation of the L-type calcium current due to a mutation in CACNB2b underlies Brugada syndrome. J Mol Cell Cardiol. 2009;46:695–703.
   PubMed Web of Science ®Google Scholar
• Antzelevitch C, Pollevick GD, Cordeiro JM, et al. Loss-of-function mutations in the cardiac calcium channel underline a new clinical entity characterized by ST segment elevation, short QT intervals, and sudden cardiac death. Circ Res. 2006 Nov 24;99:1279.
   Web of Science ®Google Scholar
• Gurnett CA, De WM, Campbell KP. Dual function of the voltage-dependent Ca2+ channel alpha 2 delta subunit in current stimulation and subunit interaction. Neuron. 1996 Feb;16:431–440.
   PubMed Web of Science ®Google Scholar
• Barajas-Martinez H, Hu D, Ferrer T, et al. Molecular genetic and functional association of Brugada and early repolarization syndromes with S422L missense mutation in KCNJ8. Heart Rhythm. 2012 Apr 1;9:548–555.
   PubMed Web of Science ®Google Scholar
• Hu D, Barajas-Martinez H, Medeiros-Domingo A, et al. Novel mutations in the sodium channel 2 subunit gene (SCN2B) associated with Brugada syndrome and atrial fibrillation. Circulation. 2012;126:A16521.
   Web of Science ®Google Scholar
• Riuro H, Beltran-Alvarez P, Tarradas A, et al. A missense mutation in the sodium channel ß2 subunit reveals SCN2B as a new candidate gene for Brugada syndrome. Hum Mutat. 2013;34:961–966.
   PubMed Web of Science ®Google Scholar
• Delpon E, Cordeiro JM, Nunez L, et al. Functional effects of KCNE3 mutation and its role in the development of Brugada syndrome. Circ Arrhythm Electrophysiol. 2008;1:209–218.
   PubMed Web of Science ®Google Scholar
• Olesen MS, Jensen NF, Holst AG, et al. A novel nonsense variant in Nav1.5 cofactor MOG1 eliminates its sodium current increasing effect and may increase the risk of arrhythmias. Can J Cardiol. 2011;27:523.e17-523.e23.
   PubMed Web of Science ®Google Scholar
• Cerrone M, Lin X, Zhang M, et al. Missense mutations in plakophilin-2 cause sodium current deficit and associate with a Brugada syndrome phenotype. Circulation. 2014 Mar 11;129:1092–1103.
   PubMed Web of Science ®Google Scholar
• Hennessey JA, Marcou CA, Wang C, et al. FGF12 is a candidate Brugada syndrome locus. Heart Rhythm. 2013 Nov 1;10:1886–1894.
   PubMed Web of Science ®Google Scholar
• Bezzina CR, J B, Mizusawa Y, et al. Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death. Nat Genet. 2013 Aug 28;45:1044–1049.
   PubMed Web of Science ®Google Scholar
• Boukens BJ, Sylva M, de Gier-de Vries C, et al. Reduced sodium channel function unmasks residual embryonic slow conduction in the adult right ventricular outflow tract. Circ Res. 2013 Jul 5;113:137–141.
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Takahashi N, Ohno S, et al. Novel SCN3B mutation associated with Brugada syndrome affects intracellular trafficking and function of Nav1.5. Circ J. 2013;77:959–967.
   PubMed Web of Science ®Google Scholar
• Weiss R. Clinical and molecular heterogeneity in the brugada syndrome: a novel gene locus on chromosome 3. Circulation. 2001;105:707–713.
   Web of Science ®Google Scholar
• Hu D, Barajas-Martinez H, Medeiros-Domingo A, et al. A novel rare variant in SCN1Bb linked to Brugada syndrome and SIDS by combined modulation of Na(v)1.5 and K(v)4.3 channel currents. Heart Rhythm. 2012 Jan 5;9:760–769.
   PubMed Web of Science ®Google Scholar
• Behr ER, Savio-Galimberti E, Barc J, et al. Role of common and rare variants in SCN10A: results from the Brugada syndrome QRS locus gene discovery collaborative study. Cardiovasc Res. 2015 Jun 1;106:520–529.
   PubMed Web of Science ®Google Scholar
• Hu D, Barajas-Martinez H, Pfeiffer R, et al. Mutations in SCN10A are responsible for a large fraction of cases of Brugada syndrome. J Am Coll Cardiol. 2014 Jul 8;64:66–79.
   PubMed Web of Science ®Google Scholar
• Liu H, Chatel S, Simard C, et al. Molecular genetics and functional anomalies in a series of 248 Brugada cases with 11 mutations in the TRPM4 channel. PLoS ONE. 2013;8:e54131.
   PubMed Web of Science ®Google Scholar
• Perrin MJ, Adler A, Green S, et al. Evaluation of genes encoding for the transient outward current (Ito) identifies the KCND2 gene as a cause of J wave syndrome associated with sudden cardiac death. Circ Cardiovasc Genet. 2014 Sep 11;7:782–789.
   PubMed Web of Science ®Google Scholar
• Verkerk AO, Wilders R, Schulze-Bahr E, et al. Role of sequence variations in the human ether-a-go-go-related gene (HERG, KCNH2) in the Brugada syndrome. Cardiovasc Res. 2005 Dec 1;68:441–453.
   PubMed Web of Science ®Google Scholar
• Wilders R, Verkerk AO. Role of the R1135H KCNH2 mutation in Brugada syndrome. IntJ Cardiol. 2010 Sept 24;144:149–151.
   PubMed Web of Science ®Google Scholar
• Ohno S, Zankov DP, Ding WG, et al. KCNE5 (KCNE1L) variants are novel modulators of Brugada syndrome and idiopathic ventricular fibrillation. Circ ArrhythmElectrophysiol. 2011 Jun 1;4:352–361.
   PubMed Web of Science ®Google Scholar
• Boczek NJ, Ye D, Johnson EK, et al. Characterization of SEMA3A-encoded semaphorin as a naturally occurring Kv4.3 Protein inhibitor and its contribution to Brugada syndrome. Circ Res. 2014 Aug 1;115:460–469.
   PubMed Web of Science ®Google Scholar
• Ueda K, Nakamura K, Hayashi T, et al. Functional characterization of a trafficking-defective HCN4 mutation, D553N, associated with cardiac arrhythmia. J Biol Chem. 2004 Jun 25;279:27194–27198.
   PubMed Web of Science ®Google Scholar
• Schwartz PJ, Ackerman MJ, George AL Jr., et al. Impact of genetics on the clinical management of channelopathies. J Am Coll Cardiol. 2013 Jul 16;62:169–180.
   PubMed Web of Science ®Google Scholar
• Antzelevitch C. Androgens and male predominance of the Brugada syndrome phenotype. Pacing Clin Electrophysiol. 2003 Jul;26:1429–1431.
   PubMed Web of Science ®Google Scholar
• Korte AK, Derde L, van Wijk J, et al. Sudden cardiac arrest as a presentation of Brugada syndrome unmasked by thyroid storm. BMJ Case Reports. 2015;2015. doi:10.1136/bcr-2015-212351.
   PubMedGoogle Scholar
• Nademanee K, Raju H, de Noronha SV, et al. Fibrosis, connexin-43, and conduction abnormalities in the Brugada syndrome. J Am Coll Cardiol. 2015 Nov 3;66:1976–1986.
   PubMed Web of Science ®Google Scholar
• Gray B, Behr ER. New insights into the genetic basis of inherited arrhythmia syndromes. Circ Cardiovasc Genet. 2016 Dec;9:569–577.
   PubMed Web of Science ®Google Scholar
• Gollob MH, Blier L, Brugada R, et al. Recommendations for the use of genetic testing in the clinical evaluation of inherited cardiac arrhythmias associated with sudden cardiac death: Canadian Cardiovascular Society/Canadian Heart Rhythm Society joint position paper. Can J Cardiol. 2011;27:232–245.
   PubMed Web of Science ®Google Scholar
• Volders PG, Sipido KR, Carmeliet E, et al. Repolarizing K+ currents ITO1 and IKs are larger in right than left canine ventricular midmyocardium. Circulation. 1999 Jan 19;99:206–210.
   PubMed Web of Science ®Google Scholar
• Antzelevitch C. Brugada syndrome. Pacing ClinElectrophysiol. 2006 Oct;29:1130–1159.
   PubMed Web of Science ®Google Scholar
• Badri M, Patel A, Yan G. Cellular and ionic basis of J-wave syndromes. Trends Cardiovasc Med. 2015 Jan;25:12–21.
   PubMed Web of Science ®Google Scholar
• Antzelevitch C. The Brugada syndrome: ionic basis and arrhythmia mechanisms. J Cardiovasc Electrophysiol. 2001 Feb;12:268–272.
   PubMed Web of Science ®Google Scholar
• Fish JM, Antzelevitch C. Role of sodium and calcium channel block in unmasking the Brugada syndrome. Heart Rhythm. 2004 Jul;1:210–217.
   PubMed Web of Science ®Google Scholar
• Yan GX, Antzelevitch C. Cellular basis for the electrocardiographic J wave. Circulation. 1996 Jan 15;93:372–379.
   PubMed Web of Science ®Google Scholar
• Di Diego JM, Cordeiro JM, Goodrow RJ, et al. Ionic and cellular basis for the predominance of the Brugada syndrome phenotype in males. Circulation. 2002;106:2004–2011.
   PubMed Web of Science ®Google Scholar
• Wilde AA, Postema PG, Di Diego JM, et al. The pathophysiological mechanism underlying Brugada syndrome: depolarization versus repolarization. J Mol Cell Cardiol. 2010;49:543–553.
   PubMed Web of Science ®Google Scholar
• Morita H, Zipes DP, Wu J. Brugada syndrome: insights of ST elevation, arrhythmogenicity, and risk stratification from experimental observations. Heart Rhythm. 2009 Nov;6:S34–S43.
   PubMed Web of Science ®Google Scholar
• Hoogendijk MG, Opthof T, Postema PG, et al. The Brugada ECG pattern: a marker of channelopathy, structural heart disease, or neither? Toward a unifying mechanism of the Brugada syndrome. Circ ArrhythmElectrophysiol. 2010 Jun 1;3:283–290.
   PubMed Web of Science ®Google Scholar
• Nademanee K, Veerakul G, Chandanamattha P, et al. Prevention of ventricular fibrillation episodes in Brugada syndrome by catheter ablation over the anterior right ventricular outflow tract epicardium. Circulation. 2011 Mar 29;123:1270–1279.
   PubMed Web of Science ®Google Scholar
• Brugada J, Pappone C, Berruezo A, et al. Brugada syndrome phenotype elimination by epicardial substrate ablation. Circ Arrhythm Electrophysiol. 2015 Aug 19.
   Web of Science ®Google Scholar
• Sacher F, Jesel L, Jais P, et al. Insight into the mechanism of Brugada syndrome: epicardial substrate and modification during ajmaline testing. Heart Rhythm. 2014 Apr 1;11:732–734.
   PubMed Web of Science ®Google Scholar
• Szel T, Antzelevitch C. Abnormal repolarization as the basis for late potentials and fractionated electrograms recorded from epicardium in experimental models of Brugada syndrome. J Am Coll Cardiol. 2014 May 20;63:2037–2045.
   PubMed Web of Science ®Google Scholar
• Patocskai B, Yoon N, Antzelevitch C. Mechanisms underlying epicardial radiofrequency ablation to suppress arrhythmogenesis in experimental models of Brugada syndrome. JACC: Clin Electrophysiol. 2017 April 1;3:353.
   PubMedGoogle Scholar
• Leong KMW, Ng FS, Yao C, et al. ST-elevation magnitude correlates with right ventricular outflow tract conduction delay in type I Brugada ECG. Circ Arrhythm Electrophysiol. 2017 Oct;10.
   Web of Science ®Google Scholar
• Antzelevitch C, Patocskai B. Ajmaline-induced slowing of conduction in the right ventricular outflow tract cannot account for ST elevation in patients with type I Brugada ECG. Circ Arrhythm Electrophysiol. 2017 Oct;10:e005775.
   Web of Science ®Google Scholar
• Elizari MV, Levi R, Acunzo RS, et al. Abnormal expression of cardiac neural crest cells in heart development: a different hypothesis for the etiopathogenesis of Brugada syndrome. Heart Rhythm. 2007;4:359–365.
   PubMed Web of Science ®Google Scholar
• Haissaguerre M, Extramiana F, Hocini M, et al. Mapping and ablation of ventricular fibrillation associated with long-QT and Brugada syndromes. Circulation. 2003 Aug 26;108:925–928.
   PubMed Web of Science ®Google Scholar
• Mont L, Bisbal F, Hernandez-Madrid A, et al. Catheter ablation vs. antiarrhythmic drug treatment of persistent atrial fibrillation: a multicentre, randomized, controlled trial (SARA study). Eur Heart J. 2014;35:501–507.
   PubMed Web of Science ®Google Scholar
• van den Berg MP, Wilde AA, Viersma TJW, et al. Possible bradycardic mode of death and successful pacemaker treatment in a large family with features of long QT syndrome type 3 and Brugada syndrome. J Cardiovasc Electrophysiol. 2001;12:630–636.
   PubMed Web of Science ®Google Scholar
• Lee KL, Lau C, Tse H, et al. Prevention of ventricular fibrillation by pacing in a man with Brugada syndrome. J Cardiovasc Electrophysiol. 2000;11:935–937.
   PubMed Web of Science ®Google Scholar
• Brugada J, Brugada R, Brugada P. Right bundle-branch block and ST-segment elevation in leads V1 through V3: a marker for sudden death in patients without demonstrable structural heart disease. Circulation. 1998 Feb 10;97:457–460.
   PubMed Web of Science ®Google Scholar
• Shimizu W, Antzelevitch C, Suyama K, et al. Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J Cardiovasc Electrophysiol. 2000;11:1320–1329.
   PubMed Web of Science ®Google Scholar
• Matana A, Goldner V, Stanic K, et al. Unmasking effect of propafenone on the concealed form of the Brugada phenomenon. Pacing Clin Electrophysiol. 2000;23:416–418.
   PubMed Web of Science ®Google Scholar
• Brugada R, Brugada J, Antzelevitch C, et al. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. Circulation. 2000 Feb 8;101:510–515.
   PubMed Web of Science ®Google Scholar
• Dakkak M, Baxi K, Patel A. Beneficial effects of isoproterenol and quinidine in the treatment of ventricular fibrillation in Brugada syndrome. Case Rep Cardiol. 2015;2015:753537.
   PubMedGoogle Scholar
• Marquez MF, Salica G, Hermosillo AG, et al. Ionic basis of pharmacological therapy in Brugada syndrome. J Cardiovasc Electrophysiol. 2007;18:234–240.
   PubMed Web of Science ®Google Scholar
• Jongman JK, Jepkes-Bruin N, Ramdat Misier AR, et al. Electrical storms in Brugada syndrome successfully treated with isoproterenol infusion and quinidine orally. Neth Heart J. 2007;15:151–155.
   PubMed Web of Science ®Google Scholar
• Fish JM, Extramiana F, Antzelevitch C. Tedisamil abolishes the arrhythmogenic substrate responsible for VT/VF in an experimental model of the Brugada syndrome. Heart Rhythm. 2004 May;1(1S):S158.
   Google Scholar
• Fish JM, Extramiana F, Antzelevitch C. AVE0118, an Ito and IKur blocker, suppresses VT/VF in an experimental model of the Brugada syndrome. Circulation. 2004 Oct 26;110(17):III–193.
   Web of Science ®Google Scholar
• Minoura Y, Panama BK, Nesterenko VV, et al. Effect of Wenxin Keli and quinidine to suppress arrhythmogenesis in an experimental model of Brugada syndrome. Heart Rhythm. 2013 Jul 1;10:1054–1062.
   PubMed Web of Science ®Google Scholar
• Brugada J, Brugada R, Brugada P. Pharmacological and device approach to therapy of inherited cardiac diseases associated with cardiac arrhythmias and sudden death. JElectrocardiol. 2000;33(Suppl):41–47.
   PubMed Web of Science ®Google Scholar
• Nademanee K, Veerakul G, Mower M, et al. Defibrillator versus beta-blockers for unexplained death in Thailand (DEBUT): a randomized clinical trial. Circulation. 2003;107:2221–2226.
   PubMed Web of Science ®Google Scholar
• Sacher F, Probst V, Maury P, et al. Outcome after implantation of cardioverter-defibrillator in patients with Brugada syndrome: a multicenter study - part 2. Circulation. 2013 Oct 15;128:1739–1747.
   PubMed Web of Science ®Google Scholar
• Gonzalez Corcia MC, Sieira J, Pappaert G, et al. Implantable cardioverter-defibrillators in children and adolescents with Brugada syndrome. J Am Coll Cardiol. 2018 Jan 16;71:148–157.
   PubMed Web of Science ®Google Scholar
• Sacher F, Probst V, Bessouet M, et al. Remote implantable cardioverter defibrillator monitoring in a Brugada syndrome population. Europace. 2009;11:489–494.
   PubMedGoogle Scholar
• De Maria E, Olaru A, Cappelli S. The entirely subcutaneous defibrillator (S-ICD): state of the art and selection of the ideal candidate. Current Cardiology Reviews. 2015;11:180–186.
   PubMed Web of Science ®Google Scholar
• Conte G, Kawabata M, De Asmundis C, et al. High rate of subcutaneous implantable cardioverter-defibrillator sensing screening failure in patients with Brugada syndrome: a comparison with other inherited primary arrhythmia syndromes. Europace. 2017 Mar 7.
   Google Scholar
• Makimoto H, Kamakura S, Aihara N, et al. Clinical impact of the number of extrastimuli in programmed electrical stimulation in patients with Brugada type 1 electrocardiogram. Heart Rhythm. 2012;9:242–248.
   PubMed Web of Science ®Google Scholar
• Nakagawa E, Takagi M, Tatsumi H, et al. Successful radiofrequency catheter ablation for electrical storm of ventricular fibrillation in a patient with Brugada syndrome. Circ J. 2008;72:1025–1029.
   PubMed Web of Science ®Google Scholar
• Shah AJ, Hocini M, Lamaison D, et al. Regional substrate ablation abolishes Brugada syndrome. J Cardiovasc Electrophysiol. 2011 Nov 1;22:1290–1291.
   PubMed Web of Science ®Google Scholar
• Cortez-Dias N, Placido R, Marta L, et al. Epicardial ablation for prevention of ventricular fibrillation in a patient with Brugada syndrome. Rev Port Cardiol. 2014;33:305.
   PubMedGoogle Scholar
• Sunsaneewitayakul B, Yao Y, Thamaree S, et al. Endocardial mapping and catheter ablation for ventricular fibrillation prevention in Brugada syndrome. J Cardiovasc Electrophysiol. 2012 Nov;23(Suppl 1):S10–S6.
   PubMed Web of Science ®Google Scholar
• Patocskai B, Antzelevitch C. Novel therapeutic strategies for the management of ventricular arrhythmias associated with the Brugada syndrome. Expert Opinion on Orphan Drugs. 2015;3:633–651.
   PubMed Web of Science ®Google Scholar
• Chinushi M, Aizawa Y, Ogawa Y, et al. Discrepant drug action of disopyramide on ECG abnormalities and induction of ventricular arrhythmias in a patient with Brugada syndrome. JElectrocardiol. 1997;30:133–136.
   PubMed Web of Science ®Google Scholar
• Yan GX, Antzelevitch C. Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation. Circulation. 1999;100:1660–1666.
   PubMed Web of Science ®Google Scholar
• Gurabi Z, Koncz I, Patocskai B, et al. Cellular mechanism underlying hypothermia-induced VT/VF in the setting of early repolarization and the protective effect of quinidine, cilostazol and milrinone. Circ Arrhythm Electrophysiol. 2014 Feb 1;7:134–142.
   PubMed Web of Science ®Google Scholar
• Alings M, Dekker L, Sadee A, et al. Quinidine induced electrocardiographic normalization in two patients with Brugada syndrome. Pacing ClinElectrophysiol. 2001;24:1420–1422.
   PubMed Web of Science ®Google Scholar
• Belhassen B, Viskin S. Pharmacologic approach to therapy of Brugada syndrome: quinidine as an alternative to ICD therapy? In: Antzelevitch C, Brugada P, Brugada J, editors. The Brugada syndrome: from bench to bedside. Oxford: Blackwell Futura; 2004. p. 202–211.
   Google Scholar
• Viskin S, Wilde AA, Tan HL, et al. Empiric quinidine therapy for asymptomatic Brugada syndrome: time for a prospective registry. Heart Rhythm. 2009;6:401–404.
   PubMed Web of Science ®Google Scholar
• Belhassen B, Glick A, Viskin S. Excellent long-term reproducibility of the electrophysiologic efficacy of quinidine in patients with idiopathic ventricular fibrillation and Brugada syndrome. Pacing Clin Electrophysiol. 2009 Mar;32:294–301.
   PubMed Web of Science ®Google Scholar
• Marquez MF, Bonny A, Hernandez-Castillo E, et al. Long-term efficacy of low doses of quinidine on malignant arrhythmias in Brugada syndrome with an implantable cardioverter-defibrillator: A case series and literature review. Heart Rhythm. 2013;9:1995–2000.
   Web of Science ®Google Scholar
• Pellegrino PL, Di BM, Brunetti ND. Quinidine for the management of electrical storm in an old patient with Brugada syndrome and syncope. Acta Cardiol. 2013 Apr;68:201–203.
   PubMed Web of Science ®Google Scholar
• Belhassen B, Viskin S, Fish R, et al. Effects of electrophysiologic-guided therapy with Class IA antiarrhythmic drugs on the long-term outcome of patients with idiopathic ventricular fibrillation with or without the Brugada syndrome. J Cardiovasc Electrophysiol. 1999;10:1301–1312.
   PubMed Web of Science ®Google Scholar
• Belhassen B, Viskin S, Antzelevitch C. The Brugada syndrome: is an implantable cardioverter defibrillator the only therapeutic option? Pacing Clin Electrophysiol. 2002 Nov;25:1634–1640.
   PubMed Web of Science ®Google Scholar
• Mok NS, Chan NY, Chi-Suen CA. Successful use of quinidine in treatment of electrical storm in Brugada syndrome. Pacing Clin Electrophysiol. 2004 Jun;27:821–823.
   PubMed Web of Science ®Google Scholar
• Bouzeman A, Traulle S, Messali A, et al. Long-term follow-up of asymptomatic Brugada patients with inducible ventricular fibrillation under hydroquinidine. Europace. 2014 Apr;16:572–577.
   PubMed Web of Science ®Google Scholar
• Burashnikov A, Petroski A, Hu D, et al. Atrial-selective inhibition of sodium channel current by Wenxin Keli is effective in suppressing atrial fibrillation. Heart Rhythm. 2012;9:125–131.
   PubMed Web of Science ®Google Scholar
• Wang X, Wang X, Gu Y, et al. Wenxin Keli attenuates ischemia-induced ventricular arrhythmias in rats: involvement of Ltype calcium and transient outward potassium currents. Mol Med Report. 2013;7:519–524.
   PubMed Web of Science ®Google Scholar
• Sugao M, Fujiki A, Nishida K, et al. Repolarization dynamics in patients with idiopathic ventricular fibrillation: pharmacological therapy with bepridil and disopyramide. J Cardiovasc Pharmacol. 2005;45:545–549.
   PubMed Web of Science ®Google Scholar
• Ohgo T, Okamura H, Noda T, et al. Acute and chronic management in patients with Brugada syndrome associated with electrical storm of ventricular fibrillation. Heart Rhythm. 2007;4:695–700.
   PubMed Web of Science ®Google Scholar
• Murakami M, Nakamura K, Kusano KF, et al. Efficacy of low-dose bepridil for prevention of ventricular fibrillation in patients with Brugada syndrome with and without SCN5A mutation. J Cardiovasc Pharmacol. 2010;56:389–395.
   PubMed Web of Science ®Google Scholar
• Aizawa Y, Yamakawa H, Takatsuki S, et al. Efficacy and safety of bepridil for prevention of ICD shocks in patients with Brugada syndrome and idiopathic ventricular fibrillation. IntJ Cardiol. 2013 Oct 12;168:5083–5085.
   PubMed Web of Science ®Google Scholar
• Kang L, Zheng MQ, Morishima M, et al. Bepridil up-regulates cardiac Na+ channels as a long-term effect by blunting proteasome signals through inhibition of calmodulin activity. Br J Pharmacol. 2009;157:404–414.
   PubMed Web of Science ®Google Scholar
• Wu HJ, Sun HY, Wu W, et al. Properties and molecular determinants of the natural flavone acacetin for blocking hKv4.3 channels. PLoS ONE. 2013;8:e57864.
   PubMed Web of Science ®Google Scholar
• Tsuchiya T, Ashikaga K, Honda T, et al. Prevention of ventricular fibrillation by cilostazol, an oral phosphodiesterase inhibitor, in a patient with Brugada syndrome. J Cardiovasc Electrophysiol. 2002;13:698–701.
   PubMed Web of Science ®Google Scholar
• Kyriazis K, Bahlmann E. van der SH, et al. Electrical storm in Brugada syndrome successfully treated with orciprenaline; effect of low-dose quinidine on the electrocardiogram. Europace. 2009 May;11:665–666.
   PubMed Web of Science ®Google Scholar
• Schweizer PA, Becker R, Katus HA, et al. Successful acute and long-term management of electrical storm in Brugada syndrome using orciprenaline and quinine/quinidine. Clin Res Cardiol. 2010;99:467–470.
   PubMed Web of Science ®Google Scholar
• Shimizu W, Matsuo K, Takagi M, et al. Body surface distribution and response to drugs of ST segment elevation in Brugada syndrome: clinical implication of eighty-seven-lead body surface potential mapping and its application to twelve-lead electrocardiograms. J Cardiovasc Electrophysiol. 2000;11:396–404.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Torigoe K, Numata O, et al. Infant case with a malignant form of Brugada syndrome. J Cardiovasc Electrophysiol. 2000 Nov 20;11:1277–1280.
   PubMed Web of Science ®Google Scholar
• Tanaka H, Kinoshita O, Uchikawa S, et al. Successful prevention of recurrent ventricular fibrillation by intravenous isoproterenol in a patient with Brugada syndrome. Pacing ClinElectrophysiol. 2001;24:1293–1294.
   PubMed Web of Science ®Google Scholar
• Agac MT, Erkan H, Korkmaz L. Conversion of Brugada type I to type III and successful control of recurrent ventricular arrhythmia with cilostazol. Arch Cardiovasc Dis. 2014 Aug-Sep;107:476–478.
   PubMed Web of Science ®Google Scholar
• Bai Y, Muqier, Murakami H, et al. Cilostazol protects the heart against ischaemia reperfusion injury in a rabbit model of myocardial infarction: focus on adenosine, nitric oxide and mitochondrial ATP-sensitive potassium channels. Clin Exp Pharmacol Physiol. 2011;38:658–665.
   PubMed Web of Science ®Google Scholar
• Shinohara T, Ebata Y, Ayabe R, et al. Combination therapy of cilostazol and bepridil suppresses recurrent ventricular fibrillation related to J-wave syndromes. Heart Rhythm. 2014 Aug 1;11:1441–1445.
   PubMed Web of Science ®Google Scholar
• Abud A, Bagattin D, Goyeneche R, et al. Failure of cilostazol in the prevention of ventricular fibrillation in a patient with Brugada syndrome. J Cardiovasc Electrophysiol. 2006;17:210–212.
   PubMed Web of Science ®Google Scholar
• Szel T, Koncz I, Antzelevitch C. Cellular mechanisms underlying the effects of milrinone and cilostazol to suppress arrhythmogenesis associated with Brugada syndrome. Heart Rhythm. 2013 Aug 1;10:1720–1727.
   PubMed Web of Science ®Google Scholar
• Fish JM, Welchons DR, Kim YS, et al. Dimethyl lithospermate B, an extract of danshen, suppresses arrhythmogenesis associated with the Brugada syndrome. Circulation. 2006 Mar 13;113:1393–1400.
   PubMed Web of Science ®Google Scholar
• Matsuo K, Akahoshi M, Seto S, et al. Disappearance of the Brugada-type electrocardiogram after surgical castration: a role for testosterone and an explanation for the male preponderance. Pacing Clin Electrophysiol. 2003;26:1551–1553.
   PubMed Web of Science ®Google Scholar
• Shimizu W, Matsuo K, Kokubo Y, et al. Sex hormone and gender difference–role of testosterone on male predominance in Brugada syndrome. J Cardiovasc Electrophysiol. 2007;18:415–421.
   PubMed Web of Science ®Google Scholar
• Yamaki M, Sato N, Okada M, et al. A case of Brugada syndrome in which diurnal ECG changes were associated with circadian rhythms of sex hormones. Int Heart J. 2009;50:669–676.
   PubMed Web of Science ®Google Scholar